Iron oxide nanoflowers encapsulated in thermosensitive fluorescent liposomes for hyperthermia treatment of lung adenocarcinoma

Theodosiou, Maria; Sakellis, Elias; Boukos, Nikos; Kusigerski, Vladan; Kalska-Szostko, B.; Efthimiadou, Eleni K.

doi:10.1038/s41598-022-12687-3

Cited by 24 publications

(9 citation statements)

References 69 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is of major importance that nanoparticles aiming to serve as theranostic agents have minimal interactions with blood components so as not to compromise their systemic administration. To this end, nanosystems such as iron oxide or gold nanoparticles must prove their biocompatibility before being intravenously injected into a living organism [ 61 , 62 ]. In our case, all samples exhibited minimal hemoglobin release from the RBCs, indicating negligible hemolysis according to the <10% acceptance limit for biopharmaceuticals [ 63 ].…”

Section: Resultsmentioning

confidence: 99%

Preliminary Evaluation of Iron Oxide Nanoparticles Radiolabeled with 68Ga and 177Lu as Potential Theranostic Agents

et al. 2022

View full text Add to dashboard Cite

Theranostic radioisotope pairs such as Gallium-68 (68Ga) for Positron Emission Tomography (PET) and Lutetium-177 (177Lu) for radioisotopic therapy, in conjunction with nanoparticles (NPs), are an emerging field in the treatment of cancer. The present work aims to demonstrate the ability of condensed colloidal nanocrystal clusters (co-CNCs) comprised of iron oxide nanoparticles, coated with alginic acid (MA) and stabilized by a layer of polyethylene glycol (MAPEG) to be directly radiolabeled with 68Ga and its therapeutic analog 177Lu. 68Ga/177Lu- MA and MAPEG were investigated for their in vitro stability. The biocompatibility of the non-radiolabeled nanoparticles, as well as the cytotoxicity of MA, MAPEG, and [177Lu]Lu-MAPEG were assessed on 4T1 cells. Finally, the ex vivo biodistribution of the 68Ga-labeled NPs as well as [177Lu]Lu-MAPEG was investigated in normal mice. Radiolabeling with both radioisotopes took place via a simple and direct labelling method without further purification. Hemocompatibility was verified for both NPs, while MTT studies demonstrated the non-cytotoxic profile of the nanocarriers and the dose-dependent toxicity for [177Lu]Lu-MAPEG. The radiolabeled nanoparticles mainly accumulated in RES organs. Based on our preliminary results, we conclude that MAPEG could be further investigated as a theranostic agent for PET diagnosis and therapy of cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Preliminary Evaluation of Iron Oxide Nanoparticles Radiolabeled with 68Ga and 177Lu as Potential Theranostic Agents

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Researchers also found that the proliferation of lung cancer cells was slowed by SPIONs coated with silica monolayers, as shown in Table 3 [ 315 ]. In another study, researchers discovered that iron oxide nanoflowers loaded in thermo-sensitive fluorescent liposomes could enhance the efficacy of cytotoxic drugs against lung cancer by causing hypothermia [ 316 ].…”

Section: Novel Nanocarriers Based Treatment Approachmentioning

confidence: 99%

Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer

Sarma,

Akther,

Ahmad

et al. 2024

Molecules

View full text Add to dashboard Cite

Lung cancer has the lowest survival rate due to its late-stage diagnosis, poor prognosis, and intra-tumoral heterogeneity. These factors decrease the effectiveness of treatment. They release chemokines and cytokines from the tumor microenvironment (TME). To improve the effectiveness of treatment, researchers emphasize personalized adjuvant therapies along with conventional ones. Targeted chemotherapeutic drug delivery systems and specific pathway-blocking agents using nanocarriers are a few of them. This study explored the nanocarrier roles and strategies to improve the treatment profile’s effectiveness by striving for TME. A biofunctionalized nanocarrier stimulates biosystem interaction, cellular uptake, immune system escape, and vascular changes for penetration into the TME. Inorganic metal compounds scavenge reactive oxygen species (ROS) through their photothermal effect. Stroma, hypoxia, pH, and immunity-modulating agents conjugated or modified nanocarriers co-administered with pathway-blocking or condition-modulating agents can regulate extracellular matrix (ECM), Cancer-associated fibroblasts (CAF),Tyro3, Axl, and Mertk receptors (TAM) regulation, regulatory T-cell (Treg) inhibition, and myeloid-derived suppressor cells (MDSC) inhibition. Again, biomimetic conjugation or the surface modification of nanocarriers using ligands can enhance active targeting efficacy by bypassing the TME. A carrier system with biofunctionalized inorganic metal compounds and organic compound complex-loaded drugs is convenient for NSCLC-targeted therapy.

show abstract

“…75 Alternatively, the encapsulation of magnetic NPs into liposomes, both produced synthetically or by magnetotactic bacteria, results also in a potential strategy for enhanced therapeutic heating. [76][77][78] Nevertheless, it is important to note that the establishment of dipolar interactions between iron oxide NPs can have positive but also negative effects on the heating performance depending on several parameters. 79,80…”

Section: Surface Coatingmentioning

confidence: 99%